Composition for the treatment of neurological post-viral infection syndromes

Abstract

The invention relates to a composition comprising an amino acid complex selected from a D-amino acid combination and other ingredients for the treatment of neurological post-viral infection syndromes.

Description

[0001] The invention relates to a composition comprising an amino acid complex selected from a D-amino acid combination and other ingredients for the treatment of neurological post-viral infection syndromes. background

[0002] Post-viral illnesses are currently not comprehensively researched. The sometimes severe long-term effects associated with COVID-19 disease have recently become known. Some research studies are examining these consequences of COVID infection and are producing supposedly new insights. The so-called post-viral fatigue syndrome has recently come into focus. It is characterized by prolonged severe exhaustion, persistent fatigue, and reduced performance as a result of an infection. However, post-viral syndrome is not a new, coronavirus-specific phenomenon. It has been described in connection with many viral infectious diseases, such as influenza, herpes zoster infections, or mononucleosis (Epstein-Barr virus), where it can even be a cause of the exhaustion and pain disorder fibromyalgia or chronic fatigue syndrome (CFS).Overall, it can be assumed that there is irritation of the nervous system, which can be treated with a suitable composition.

[0003] With a herpes zoster infection, nerve pain can persist for a long time even after the rash has healed. This type of infection usually causes a painful rash. The pain usually disappears after two to four weeks as the rash clears. If it persists for more than three months, it is called post-herpetic neuralgia. Very rarely, the pain returns after it has already cleared.

[0004] The main symptom of post-herpetic neuralgia is nerve pain (neuralgia). The skin is often also hypersensitive and itchy. The pain and itching can be very distressing and disrupt sleep. They can last for weeks, months, or even years.

[0005] The object of the present invention was therefore to provide a composition which is suitable for the treatment of neurological post-viral infection syndromes.

[0006] In a website at https: / / web.archive.org / web / 20231201032544 / https: / / www.sanopo ly.com / de / shop / kopf-und-gehirn / priosa-nerv-vitalstoffmixfuer-das-nervensystem-aus-der-aerztlichen-praxis-4260483470424.html, SANOPOLY discloses a composition for the treatment of type 2 diabetes mellitus, without disclosing its exact composition. Brief description of the invention

[0007] The invention provides a composition as set out in claim 1. Further embodiments of the invention are found in the subclaims.

[0008] The composition comprises an amino acid complex selected from a D-amino acid combination selected from the group consisting of D-tryptophan, D-methionine, D-asparagine and / or aspartic acid, and D-glutamine and / or D-glutamic acid.

[0009] It is further preferred that the composition comprises R-alpha-lipoic acid, active vitamin B6, active folic acid and vitamin B12 (as adenosylcobalamin).

[0010] It is further preferred that the composition comprises phosphatidylserine and / or lecithin.

[0011] It is further preferred that the composition comprises vitamin K2.

[0012] The invention further provides a dietary food for special medical purposes or a food supplement comprising a composition as described herein.

[0013] The invention further relates to a dietary food for special medical purposes or a dietary supplement as described herein for the relief of neurological post-viral infection syndromes.

[0014] The invention further relates to the use of the composition as described herein in medicine.

[0015] The invention further relates to a composition as described herein for use in the treatment of neurological post-viral infection syndromes, wherein the treatment comprises administering a therapeutically effective amount to a human. Detailed description of the invention

[0016] The composition according to the invention is able to improve the deficiency of vital substances, which manifests as neurological changes as a result of viral infection.

[0017] The uniqueness of the composition is the combination of D-amino acids. This formula is capable of regulating neurological "connections" (probably) in the sensory cortex and typically relieving symptoms within 2-4 weeks.

[0018] The invention therefore provides a composition comprising an amino acid complex selected from a D-amino acid combination selected from the group consisting of D-tryptophan, D-methionine, D-asparagine and / or D-aspartic acid, and D-glutamine or D-glutamic acid.

[0019] It is further preferred that the composition comprises R-alpha-lipoic acid, active vitamin B6, active folic acid, and vitamin B12 (adenosylcobalamin).

[0020] It is further preferred that the composition comprises phosphatidylserine and / or lecithin.

[0021] It is further preferred that the composition comprises vitamin K2.

[0022] The composition preferably contains D-tryptophan in the range of 85-95 mg, D-methionine in the range of 55-65 mg, D-asparagine in the range of 48-53 mg and / or aspartic acid in the range of 18-22 mg, and D-glutamine or D-glutamic acid in the range of 50-60 mg, based on a daily dose.

[0023] The composition also contains R-alpha-lipoic acid in the range of 180-200 mg, active vitamin B6 in the range of 20-30 mg, active folic acid in the range of 800-820 ng, vitamin B12 (methylcobalamin) in the range of 15-20 ng, based on a daily dose.

[0024] It is further preferred that phosphatidylserine and / or lecithin is contained in the composition in the range of 80-90 mg, based on a daily dose.

[0025] Furthermore, it is preferred that vitamin K2 (menaquinone) is contained in the composition in the range of 170-190 ng, based on a daily dose.

[0026] According to another embodiment of the composition according to the invention, the composition comprises approximately 5 mg of Himalayan salt. Himalayan salt is a rock salt consisting of at least 97 percent sodium chloride. It also contains a small amount of minerals such as magnesium, calcium, potassium, and trace elements such as iron and zinc.

[0027] It is particularly preferred if the composition has the following components and amounts: Connection Crowd Form of administration D-Trp 90 mg D-Met 60 mg D-Asp 51 mg D-Asn 20 mg D-Gln 31 mg D-Glu 55 mg Ra-lipoic acid 190 mg Vitamin B6 25 mg Pyridoxal-5-phosphate, this is considered the active form of the vitamin Folic acid 810 ng 5 Methyl Tetrahydrofolate Vitamin B12 18 ng Adenosylcobalamin Phosphatidylserine 85 mg Vitamin K2 180 ng Menaquinone Himalayan salt 5 mg

[0028] The composition may also contain adjuvants, disintegrants, slow-release agents, absorption enhancers, antioxidants, acidulants, thickeners, anticoagulants, colorants, flavorings, sweeteners, preservatives, and the like. These substances, if present in the composition, are present in an amount below the ADI (acceptable daily intake) and do not have any adverse effects on the human body.

[0029] The invention further provides a dietary food for special medical purposes or a food supplement comprising a composition as described herein.

[0030] The invention further relates to a dietary food for special medical purposes or a dietary supplement as described herein for the relief of neurological post-viral infection syndromes.

[0031] The dietary food for special medical purposes or the food supplement is preferably in the form of powder, tablets, capsules, sachets, or dissolved in liquid. Capsules are particularly preferred.

[0032] The dietary food for special medical purposes or food supplement is preferably administered in two doses, divided into lunch and dinner, up to the maximum daily dose. The duration of administration is determined on a case-by-case basis based on efficacy. Preferably, the dietary food or food supplement is administered for at least 1 day up to 6 months, more preferably 7 days up to 60 days.

[0033] The invention further relates to the use of the composition as described herein in medicine.

[0034] The invention further relates to a composition as described herein for use in the treatment of neurological post-viral infection syndromes, wherein the treatment comprises administering a therapeutically effective amount to a human.

[0035] The composition is preferably in the form of powder, tablets, capsules, sachets, or dissolved in liquid. Capsules are particularly preferred.

[0036] The composition is preferably administered in two to four doses, particularly two doses, distributed throughout the day up to the maximum daily dose. The duration of administration is determined on a case-by-case basis based on efficacy. The composition is preferably administered for at least 1 day to 6 months, preferably 7 days to approximately 60 days. A preferred dosage regimen comprises 0-1-1 to 0-2-2 capsules / day (morning-noon-evening).

[0037] When used as described above to treat neurological post-viral infection syndromes, the neurological post-viral infection syndromes are selected from post-herpetic neuralgia, long Covid syndrome, influenza illnesses, post-HIV syndrome, and other post-viral syndromes.

[0038] The D-amino acid combination of D-tryptophan, D-methionine, D-asparagine, and / or D-aspartic acid, D-glutamine, or D-glutamic acid is effective. Neurological post-viral infection symptoms, especially nerve pain, are quickly and noticeably alleviated.

[0039] The composition is rounded off by ingredients known to positively support nerve metabolism. These include: • R-alpha-lipoic acid, • Active vitamin B6, • Active folic acid, and • Natural B12 (adenosylcobalamin).

[0040] The effectiveness is achieved through the synergistic effects of the ingredients.

[0041] The vitamins and the coenzyme R-α-lipoic acid are the auxiliary substances for the D-amino acids in the nervous system.

[0042] The composition according to the invention interacts particularly well with the sensory cortex. It is assumed that after viral infections, such as those known in herpes zoster, neurological "connections" occur (post-herpetic neuralgia) that cannot be "reset" or are difficult to reset. Even if a viral infection is then immunologically overcome, the nerve pathways (= pain, = neurological irritation) cannot simply be switched back to their original state without the D-amino acids. This is comparable to a pain memory, which can also occur in amputations.

[0043] To support the switch-back process, phosphatidylserine (similar to lecithin) is included in the composition, which acts as an insulating material in the nerve sheaths.

[0044] Furthermore, the vitamin K2 contained in the composition has the function of facilitating faster diavascular transport. Vitamin K2 acts as a kind of transport aid for D-amino acids into the brain.

[0045] The invention will now be explained in more detail using an embodiment, which is not to be understood as limiting the scope of the invention and is for illustrative purposes only. Experimental:Example 1:

[0046] A compound was administered to 30 patients diagnosed with post-herpetic neuralgia over a period of 7 days. Another group of patients received a placebo.

[0047] In a daily dose of two capsules, the following amounts were administered: Table 1: Preferred composition Connection Crowd Form of administration D-Trp 90 mg D-Met 60 mg D-Asp 51 mg D-Asn 20 mg D-Gln 31 mg D-Glu 55 mg R-α-lipoic acid 190 mg Vitamin B6 25 mg Pyridoxal-5-phosphate, this is considered the active form of the vitamin Folic acid 810 ng 5-Methyl-Tetra-Hydrofolate Vitamin B12 18 ng Adenosylcobalamin Phosphatidylserine 85 mg Vitamin K2 180 ng Menaquinone Himalayan salt 5 mg

[0048] The composition showed effects in the selected patient groups after just three days. Neuralgia and itching disappeared or were significantly reduced. This means that on a patient-specific scale of 1-10 for pain and itching, an average reduction in symptoms of more than 80% was achieved. In 20% of patients, symptoms disappeared completely. The placebo group showed no positive effects.

[0049] In an observational study with now more than 100 post-Covid patients who were administered the composition according to the invention according to Table 1, at least 70% of the informed test subjects had a symptom improvement between 60% and 100% (improvement in intensity and symptom extent) within 4 weeks.

Claims

[1] Composition comprising a) an amino acid complex comprising a combination of D-amino acids, wherein the D-amino acids are selected from the group consisting of D-tryptophan, D-methionine, D-asparagine and / or aspartic acid, and D-glutamine and / or D-glutamic acid, b) R-alpha-lipoic acid, active vitamin B6, active folic acid, and vitamin B12 (adenosylcobalamin), c) Phosphatidylserine and / or lecithin, d) Vitamin K2, where • D-tryptophan in the range of 85-95 mg, D-methionine of 55-65 mg, D-asparagine of 48-53 mg and / or D-aspartic acid in the range of 18-22 mg, and D-glutamine and / or D-glutamic acid of 50-60 mg are included in the composition, • R-alpha-lipoic acid in the range of 180-200 mg, active vitamin B6 of 20-30 mg, active folic acid of 800-820 ng, vitamin B12 (methylcobalamin) of 15-20 ng is included in the composition, • Phosphatidylserine and / or lecithin in the range of 80-90 mg is included in the composition, and • Vitamin K2 (menaquinone) is contained in the composition in the range of 170-190 ng, each based on a daily dose. [2] The composition of claim 1, further comprising Himalayan salt. [3] The composition of claim 2, wherein the Himalayan salt is present in the range of 4.6 to 5.4 mg. [4] Composition according to any one of the preceding claims, wherein the composition comprises the following components and amounts: Connection Crowd Form of administration D-Trp 90 mg D-Met 60 mg D-Asp 51 mg D-Asn 20 mg D-Gln 31 mg D-Glu 55 mg Ra-lipoic acid 190 mg Vitamin B6 25 mg Pyridoxal-5-phosphate, as the active form of vitamin B6 Folic acid 810 ng 5-Methyl-Tetra-Hydrofolate Vitamin B12 18 ng Adenosylcobalamin Phosphatidylserine 85 mg Vitamin K2 180 ng Menaquinone Himalayan salt 5mg [5] Dietary food for special medical purposes comprising a composition according to any one of claims 1 to 4. [6] Dietary food for special medical purposes according to claim 5, which is in the form of powder, tablets, capsules, sachets or dissolved in liquid. [7] Dietary food for special medical purposes according to one of claims 5 or 6 for the alleviation of neurological post-viral infection syndromes. [8] Composition according to any one of claims 1-4 for use in medicine. [9] A composition according to any one of claims 1-4 for use in the treatment of neurological post-viral infection syndromes, wherein the treatment comprises administering to a human a therapeutically effective amount. [10] Use according to claim 9, wherein the neurological post-viral infection syndromes are selected from post-herpetic neuralgia, long Covid syndrome, post-flu syndrome, post-HIV syndrome, and other post-viral syndromes.